AFA-281 is under clinical development by AfaSci and currently in Phase I for Neuropathic Pain (Neuralgia). According to GlobalData, Phase I drugs for Neuropathic Pain (Neuralgia) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AFA-281’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AFA-281 overview
AFA-281 is under development for the treatment of osteoarthritis, cancer pain, inflammatory pain, neuropathic pain, alcohol use disorder, lumbosacral radiculopathy and cocaine use disorder. It is administered through oral and intravenous route. The drug candidate is a dual modulator acts by targeting T-type calcium channels (Cav3) and soluble epoxide hydrolase (sEH).
AfaSci overview
AfaSci is developing drugs for treating analgesia and alzheimer’s disease. The company is headquartered in Burlingame, California, the US.
For a complete picture of AFA-281’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
